Enveric Biosciences Inc (ENVB)

$0.63 +0.02 (2.56%)
Market Cap 3.91M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 509,300
Avg Vol 627,268
Day's Range N/A - N/A
Shares Out 6.22M
Stochastic %K 15%
Beta 0.60
Analysts Strong Buy
Price Target $10.00

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology
Sector: Healthcare
Address:
245 First Street, Riverview II 18 th Floor, Cambridge, United States
big_CHOCO_MIL
big_CHOCO_MIL Oct. 24 at 8:37 PM
$ENVB damn a lot of negativity here lmao. Sounds like it’s time to buy. I’m in
1 · Reply
TwongStocks
TwongStocks Oct. 24 at 7:29 PM
$ENVB NASDAQ Equity Corporate Actions Alert # 2025 - 585 Information Regarding the Reverse Stock Split and CUSIP Number Change for Enveric Biosciences, Inc. (ENVB) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-585 Enveric Biosciences, Inc. (ENVB) will effect a one-for-twelve (1-12) reverse split of its Common Stock. The reverse stock split will become effective on Tuesday, October 28, 2025. In conjunction with the reverse split, the CUSIP number will change to 29405E505.
0 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 3:27 PM
$ENVB
0 · Reply
Cretandawg
Cretandawg Oct. 24 at 2:55 PM
$ENVB lmao another split ? I’ve been holding for years and my thousand++ shares has turned into 14 shares at an average of $1,176 after the last split !!!!!!!! Now another split ? WOW pure garbage I put 18k in this thing and my market value is now $8.96 !!!! Their news always seems promising , but I wouldn’t touch this folks. Learn from my 18k lesson
1 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 2:35 PM
$ABBV their Business model is to steal intellectual properties that are patented by other companies and reap the benefits. 🤬 pay us what is rightfully ours stealing from another company and their share holder value is evil $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 1:48 PM
$ENVB parabolic 🐦‍🔥
0 · Reply
_NotFinancialAdvice_
_NotFinancialAdvice_ Oct. 24 at 1:44 PM
$ENVB is holding up well despite the r-s announcement.
0 · Reply
BackWatchonly
BackWatchonly Oct. 23 at 11:47 PM
$ENVB you will never ever have my attention again unless you turn this turd around!!!
0 · Reply
BackWatchonly
BackWatchonly Oct. 23 at 11:46 PM
$ENVB seriously...really!!!!!!!!!
1 · Reply
javier0304
javier0304 Oct. 23 at 9:18 PM
$ENVB getting in before the split
1 · Reply
Latest News on ENVB
Enveric Biosciences Announces Reverse Stock Split

Oct 23, 2025, 8:00 AM EDT - 2 days ago

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 16, 2025, 8:30 AM EDT - 9 days ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 15, 2025, 8:00 AM EDT - 10 days ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 14, 2025, 9:00 AM EDT - 11 days ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Oct 2, 2025, 8:45 AM EDT - 23 days ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 18, 2025, 4:30 PM EDT - 5 weeks ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 5 weeks ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 17, 2025, 8:00 AM EDT - 5 weeks ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 16, 2025, 8:45 AM EDT - 5 weeks ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 7 weeks ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Sep 2, 2025, 8:30 AM EDT - 7 weeks ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Aug 14, 2025, 8:00 AM EDT - 2 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 23, 2025, 8:03 AM EDT - 3 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jul 15, 2025, 9:03 AM EDT - 3 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 24, 2025, 9:03 AM EDT - 4 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 16, 2025, 10:46 AM EDT - 4 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 10, 2025, 9:03 AM EDT - 4 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Jun 3, 2025, 9:00 AM EDT - 5 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025, 9:03 AM EDT - 5 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025, 8:00 AM EDT - 5 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025, 4:15 PM EDT - 5 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 31, 2025, 8:00 AM EDT - 7 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 17, 2025, 1:40 PM EDT - 7 months ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Mar 6, 2025, 10:00 AM EST - 8 months ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 27, 2025, 9:30 AM EST - 8 months ago

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 25, 2025, 1:30 PM EST - 8 months ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 4, 2025, 8:00 AM EST - 9 months ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Feb 3, 2025, 5:00 PM EST - 9 months ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 9 months ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 30, 2025, 4:01 PM EST - 9 months ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Jan 6, 2025, 8:30 AM EST - 10 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Dec 2, 2024, 8:00 AM EST - 11 months ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 25, 2024, 9:00 AM EST - 11 months ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 14, 2024, 4:05 PM EST - 1 year ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 12, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Announces Broad Range of Patent Issuances

Nov 4, 2024, 10:36 AM EST - 1 year ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Aug 12, 2024, 5:30 PM EDT - 1 year ago

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Jul 15, 2024, 9:02 AM EDT - 1 year ago

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences Announces Patent Granted for Drug Candidate

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Patent Granted for Drug Candidate

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

MBIO

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate

Enveric Biosciences to Participate in BIO International Convention 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Participate in BIO International Convention 2024

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

May 15, 2024, 6:00 AM EDT - 1 year ago

Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results

big_CHOCO_MIL
big_CHOCO_MIL Oct. 24 at 8:37 PM
$ENVB damn a lot of negativity here lmao. Sounds like it’s time to buy. I’m in
1 · Reply
TwongStocks
TwongStocks Oct. 24 at 7:29 PM
$ENVB NASDAQ Equity Corporate Actions Alert # 2025 - 585 Information Regarding the Reverse Stock Split and CUSIP Number Change for Enveric Biosciences, Inc. (ENVB) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-585 Enveric Biosciences, Inc. (ENVB) will effect a one-for-twelve (1-12) reverse split of its Common Stock. The reverse stock split will become effective on Tuesday, October 28, 2025. In conjunction with the reverse split, the CUSIP number will change to 29405E505.
0 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 3:27 PM
$ENVB
0 · Reply
Cretandawg
Cretandawg Oct. 24 at 2:55 PM
$ENVB lmao another split ? I’ve been holding for years and my thousand++ shares has turned into 14 shares at an average of $1,176 after the last split !!!!!!!! Now another split ? WOW pure garbage I put 18k in this thing and my market value is now $8.96 !!!! Their news always seems promising , but I wouldn’t touch this folks. Learn from my 18k lesson
1 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 2:35 PM
$ABBV their Business model is to steal intellectual properties that are patented by other companies and reap the benefits. 🤬 pay us what is rightfully ours stealing from another company and their share holder value is evil $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Oct. 24 at 1:48 PM
$ENVB parabolic 🐦‍🔥
0 · Reply
_NotFinancialAdvice_
_NotFinancialAdvice_ Oct. 24 at 1:44 PM
$ENVB is holding up well despite the r-s announcement.
0 · Reply
BackWatchonly
BackWatchonly Oct. 23 at 11:47 PM
$ENVB you will never ever have my attention again unless you turn this turd around!!!
0 · Reply
BackWatchonly
BackWatchonly Oct. 23 at 11:46 PM
$ENVB seriously...really!!!!!!!!!
1 · Reply
javier0304
javier0304 Oct. 23 at 9:18 PM
$ENVB getting in before the split
1 · Reply
Luckyjs38
Luckyjs38 Oct. 23 at 6:23 PM
$ENVB
0 · Reply
RBLUCKY
RBLUCKY Oct. 23 at 6:14 PM
$ENVB
0 · Reply
Zackpedia
Zackpedia Oct. 23 at 3:10 PM
$ENVB Dont buy it until the RS, will go at least 30% down afterwards
0 · Reply
RBLUCKY
RBLUCKY Oct. 23 at 3:07 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Oct. 23 at 2:43 PM
$ENVB I’ll hold and double down post split we will get into stage 1 human trails for EB-003 early next year. I believe this is the last and final split before we unlock the hidden value held by this company. Abbvie is better off doing a settlement for the patented rights to our held intellectual property they are using in their 1.2 Billion dollar drug deal. my thoughts 50 million cash and forever royalties with their new drug would get us the cash on hand we need to get EB-003 through trails and have a long lasting revenue stream trickling in from royalties is the best case scenario in my view 🙏❤️
0 · Reply
Luckyjs38
Luckyjs38 Oct. 23 at 2:03 PM
$ABBV $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Oct. 23 at 2:02 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Oct. 23 at 2:02 PM
$BYND $ENVB
0 · Reply
edoli
edoli Oct. 23 at 1:56 PM
$ENVB oversold territory 🤑
0 · Reply
RBLUCKY
RBLUCKY Oct. 23 at 1:02 PM
$ENVB another reverse split what is this the fourth one how many times is the SEC going to allow this company to steal people shares and continue to do offerings just criminal this company needs to be reported!
0 · Reply
Gian22
Gian22 Oct. 23 at 12:10 PM
$ENVB sorry bears this RS will be different let’s see 🍀
0 · Reply
Luckyjs38
Luckyjs38 Oct. 22 at 2:42 PM
$ABBV @abbvie Business model is to steal intellectual patented properties and reap the benefits while crushing other Biopharmaceutical companies on the brink of curing Depression, anxiety,ptsd to combat the epidemic of mental illness in the world. How will we make the world a better place with evil companies suppressing The treatment needed to help millions of lives world wide? pay us whats rightfully ours $ENVB us investors deserve the benefits of our companies assets including protect patented intellectual properties
0 · Reply